Pricing And Fewer Treatments Eat At Biogen Biosimilar Sales
US-Based Firm Looking Beyond EU And Samsung Bioepis Partnership
Samsung Bioepis saw sales of its anti-TNF biosimilars in Europe drop in the first quarter of this year, though the traditionally innovative Biogen continues to look to new products and geographies to build its biosimilars presence.
You may also be interested in...
Generics Industry Fails To Match Last Year’s Growth In First Quarter
The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies.
Samsung Bioepis Nudges Closer To Ranibizumab Approvals With New Data
Samsung Bioepis has been tight-lipped on the potential to win approval for its SB11 biosimilar ranibizumab product this year, though new similarity data is a further positive omen for the Korea-based biosimilar player.
First US Lucentis Biosimilar Expected By Year End, Roche Confirms
Another of Roche’s biologic blockbusters is due to bite the dust this year, the originator has confirmed, with biosimilar competition to Lucentis forecast in the second half of 2021.